Navigace hitu: Projekce cenové trajektorie Ozempicu na americkém farmaceutickém trhu uprostřed nedostatku na trhu, konkurenčního a regulačního tlaku, vypršení platnosti patentů a internetové slávy

This thesis deals with the question of estimating the price trajectory of Novo Nordisk's Ozempic post-patent expiration on the US pharmaceutical market. It discusses various factors that have an impact on the price of the medication, including the product life cycle, the role of Pharmacy Benefit Managers, availability, competition amongst other products as well as generic versions of the same product, insurance coverage, government intervention, and patent protection. The topics are applied to the real-world example of Ozempic through an examination of Novo Nordisk strategies in relation to the product life cycle of its drugs, the Internet fame which Ozempic benefitted between 2022 and 2024, the shortage which the medication faced between 2022 and 2025, as well as the role and development of the duopoly between Novo Nordisk and rival Eli Lilly. Furthermore, it focuses on the types of users of Ozempic, their varying levels of brand loyalty, and the existence and types of insurance coverage available to them based on their diagnosis. In addition to that, it describes the role of counterfeit Ozempic in terms of competing with the branded version, the role of Most Favored Nation pricing and its resulting price reductions, and finally the patent Novo Nordisk has in place for Ozempic’s active ingredient semaglutide. After taking into account all of these aspects, an estimation of how the price of the medication is likely to behave both in the years building up to the patent expiration and the years which will follow the anticipated 2032 date were made.